ENDRA Life Sciences Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
RBSM LLP (“RBSM”) audited our financial statements for the year ended December 31, 2025. The following table sets forth the aggregate fees billed or expected to be billed by RBSM for audit and non-audit services in 2025 and 2024, including “out-of-pocket” expenses incurred in rendering these services. The nature of the services provided for each category is described following the table.
| Fee Category · 2025 · 2024 | |||
|---|---|---|---|
| Audit Fees (1) | $209,000 | $237,500 | |
| Audit-Related Fees | - | - | |
| Tax Fees (2) | - | $ | - |
| Total | $209,000 | $237,500 | |
| (1) | Audit fees include fees for professional services rendered for the audit of our annual statements, quarterly reviews, consents and assistance with and review of documents filed with the SEC. |
| (2) | Tax fees include fees for professional services rendered for tax compliance, tax advice and tax planning. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.